개인구독
소속 기관이 없으신 경우, 개인 정기구독을 하시면 저렴하게
논문을 무제한 열람 이용할 수 있어요.
지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2022.9
- 수록면
- 419 - 432 (14page)
- DOI
- 10.3947/ic.2022.0063
이용수
이 논문의 연구 히스토리 (2)
2022
Weight Gain and Lipid Profile Changes in Koreans with Human Immunodeficiency Virus undergoing Integrase Strand Transfer Inhibitor-Based Regimens
김진
,
남현주
,
정유진
외 10명
Infection and Chemotherapy
2022.09
학술저널
Weight Gain and Metabolic Changes in Korean People living with HIV Undergoing Integrase Strand Transfer Inhibitor-based Antiretroviral Therapy
김진
2022.01
학위논문
- 이 논문의 후속연구가 궁금하신가요?
- 연관 학술논문 또는 학술발표를 통해 보다 발전된 연구결과를 확인하실 수 있습니다.
- 이 논문의 연구 히스토리 확인하기
초록· 키워드
오류제보하기
Weight Gain and Lipid Profile Changes in Koreans with Human Immunodeficiency Virus undergoing Integrase Strand Transfer Inhibitor-Based Regimens Jin Kim,1 Hyun-Ju Nam,1 Yu-Jin Jung,2 Hye-Jung Lee,2 Seong-Eun Kim,1 Seung-Ji Kang,1 Kyung-Hwa Park,1 Hyun-Ha Chang,2 Shin-Woo Kim,2 Eun-Kyung Chung,3 Uh Jin Kim,1,* and Sook In Jung1,* 1Department of Infectious Diseases, Chonnam National University Medical School, Gwangju, Korea.
2Division of Infectious Diseases, Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Korea.
3Department of Medical Education, Chonnam National University Medical School, Gwangju, Korea.
Corresponding Author: Sook In Jung, MD, PhD. Department of Infectious Diseases, Chonnam National University Medical School, 42, Jebong-ro, Dong-gu, Gwangju 61469, Korea. Tel: +82-62-220-6502, Fax: +82-62-225-8578, Email: sijung@chonnam.ac.kr Corresponding Author: Uh Jin Kim, MD. Department of Infectious Diseases, Chonnam National University Medical School, 42, Jebong-ro, Dong-gu, Gwangju 61469, Korea. Tel: +82-62-220-6297, Fax: +82-62-225-8578, Email: astralio@naver.com *These authors have contributed equally to this work.
Received May 09, 2022; Accepted June 27, 2022.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Go to: Abstract
Background This study explored the relationship between integrase strand transfer inhibitor (INSTI)-based anti-retroviral agents and weight gain over time, and the risk factors for weight gain in Korean people living with human immunodeficiency virus (PLWH).
Materials and Methods The study was conducted retrospectively in PLWHs 18 years of age or older who took one of three INSTI-based single-tablet regimens (STRs) (tenofovir disoproxil fumarate/emtricitabine/elvitegravir/cobicistat [TDF/F/EVG/c], tenofovir alafenamide/emtricitabine/elvitegravir/cobicistat [TAF/F/EVG/c], and abacavir/lamivudine/dolutegravir [ABC/3TC/DTG]) for more than 2 years at three university-affiliated hospitals in South Korea from May 2014 to December 2020. Analysis was performed in the treatment-naïve and treatment-experienced groups, respectively.
Results Individual INSTI-based STRs were associated with weight gain at the 24-month follow up in both treatment-naïve (n = 179) and treatment-experienced (n = 290) groups. Body mass index (BMI) categories changed over time for TAF/F/EVG/c and ABC/3TC/DTG, with significant increases in the rates of overweight and obesity in treatment-naïve patients, whereas there was no change for TDF/F/EVG/c. TAF/F/EVG/c significantly increased total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and triglyceride (TG) compared to other regimens over 24 months. In the treatment-naïve group, a baseline CD4+ T cell count <100 cells/mm3, human immunodeficiency virus (HIV) viral load (VL) ≥100,000 copies/mL, no physical exercise, and TAF/F/EVG/c (vs. TDF/F/EVF/c) were risk factors for ≥10% weight gain. In the treatment-experienced group, age <45 years, BMI <25 kg/m2, and no physical exercise were risk factors for ≥5% weight gain.
Conclusion INSTI-based STR continued to increase body weight at the 24-month follow up in treated and untreated Korean PLWH. Exercise, together with demographic-, HIV-, and anti-retroviral therapy-related factors, influenced weight gain. Therefore, when prescribing an INSTI-based STR, weight gain and metabolic changes should be closely monitored in PLWH with these risk factors.
Weight Gain and Lipid Profile Changes in Koreans with Human Immunodeficiency Virus undergoing Integrase Strand Transfer Inhibitor-Based Regimens Jin Kim,1 Hyun-Ju Nam,1 Yu-Jin Jung,2 Hye-Jung Lee,2 Seong-Eun Kim,1 Seung-Ji Kang,1 Kyung-Hwa Park,1 Hyun-Ha Chang,2 Shin-Woo Kim,2 Eun-Kyung Chung,3 Uh Jin Kim,1,* and Sook In Jung1,* 1Department of Infectious Diseases, Chonnam National University Medical School, Gwangju, Korea. 2Division of Infectious Diseases, Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Korea. 3Department of Medical Education, Chonnam National University Medical School, Gwangju, Korea. Corresponding Author: Sook In Jung, MD, PhD. Department of Infectious Diseases, Chonnam National University Medical School, 42, Jebong-ro, Dong-gu, Gwangju 61469, Korea. Tel: +82-62-220-6502, Fax: +82-62-225-8578, Email: sijung@chonnam.ac.kr Corresponding Author: Uh Jin Kim, MD. Department of Infectious Diseases, Chonnam National University Medical School, 42, Jebong-ro, Dong-gu, Gwangju 61469, Korea. Tel: +82-62-220-6297, Fax: +82-62-225-8578, Email: astralio@naver.com *These authors have contributed equally to this work. Received May 09, 2022; Accepted June 27, 2022. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Go to: Abstract Background This study explored the relationship between integrase strand transfer inhibitor (INSTI)-based anti-retroviral agents and weight gain over time, and the risk factors for weight gain in Korean people living with human immunodeficiency virus (PLWH). Materials and Methods The study was conducted retrospectively in PLWHs 18 years of age or older who took one of three INSTI-based single-tablet regimens (STRs) (tenofovir disoproxil fumarate/emtricitabine/elvitegravir/cobicistat [TDF/F/EVG/c], tenofovir alafenamide/emtricitabine/elvitegravir/cobicistat [TAF/F/EVG/c], and abacavir/lamivudine/dolutegravir [ABC/3TC/DTG]) for more than 2 years at three university-affiliated hospitals in South Korea from May 2014 to December 2020. Analysis was performed in the treatment-naïve and treatment-experienced groups, respectively. Results Individual INSTI-based STRs were associated with weight gain at the 24-month follow up in both treatment-naïve (n = 179) and treatment-experienced (n = 290) groups. Body mass index (BMI) categories changed over time for TAF/F/EVG/c and ABC/3TC/DTG, with significant increases in the rates of overweight and obesity in treatment-naïve patients, whereas there was no change for TDF/F/EVG/c. TAF/F/EVG/c significantly increased total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and triglyceride (TG) compared to other regimens over 24 months. In the treatment-naïve group, a baseline CD4+ T cell count <100 cells/mm3, human immunodeficiency virus (HIV) viral load (VL) ≥100,000 copies/mL, no physical exercise, and TAF/F/EVG/c (vs. TDF/F/EVF/c) were risk factors for ≥10% weight gain. In the treatment-experienced group, age <45 years, BMI <25 kg/m2, and no physical exercise were risk factors for ≥5% weight gain. Conclusion INSTI-based STR continued to increase body weight at the 24-month follow up in treated and untreated Korean PLWH. Exercise, together with demographic-, HIV-, and anti-retroviral therapy-related factors, influenced weight gain. Therefore, when prescribing an INSTI-based STR, weight gain and metabolic changes should be closely monitored in PLWH with these risk factors.
Weight Gain and Lipid Profile Changes in Koreans with Human Immunodeficiency Virus undergoing Integrase Strand Transfer Inhibitor-Based Regimens Jin Kim,1 Hyun-Ju Nam,1 Yu-Jin Jung,2 Hye-Jung Lee,2 Seong-Eun Kim,1 Seung-Ji Kang,1 Kyung-Hwa Park,1 Hyun-Ha Chang,2 Shin-Woo Kim,2 Eun-Kyung Chung,3 Uh Jin Kim,1,* and Sook In Jung1,* 1Department of Infectious Diseases, Chonnam National University Medical School, Gwangju, Korea. 2Division of Infectious Diseases, Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Korea. 3Department of Medical Education, Chonnam National University Medical School, Gwangju, Korea. Corresponding Author: Sook In Jung, MD, PhD. Department of Infectious Diseases, Chonnam National University Medical School, 42, Jebong-ro, Dong-gu, Gwangju 61469, Korea. Tel: +82-62-220-6502, Fax: +82-62-225-8578, Email: sijung@chonnam.ac.kr Corresponding Author: Uh Jin Kim, MD. Department of Infectious Diseases, Chonnam National University Medical School, 42, Jebong-ro, Dong-gu, Gwangju 61469, Korea. Tel: +82-62-220-6297, Fax: +82-62-225-8578, Email: astralio@naver.com *These authors have contributed equally to this work. Received May 09, 2022; Accepted June 27, 2022. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Go to: Abstract Background This study explored the relationship between integrase strand transfer inhibitor (INSTI)-based anti-retroviral agents and weight gain over time, and the risk factors for weight gain in Korean people living with human immunodeficiency virus (PLWH). Materials and Methods The study was conducted retrospectively in PLWHs 18 years of age or older who took one of three INSTI-based single-tablet regimens (STRs) (tenofovir disoproxil fumarate/emtricitabine/elvitegravir/cobicistat [TDF/F/EVG/c], tenofovir alafenamide/emtricitabine/elvitegravir/cobicistat [TAF/F/EVG/c], and abacavir/lamivudine/dolutegravir [ABC/3TC/DTG]) for more than 2 years at three university-affiliated hospitals in South Korea from May 2014 to December 2020. Analysis was performed in the treatment-naïve and treatment-experienced groups, respectively. Results Individual INSTI-based STRs were associated with weight gain at the 24-month follow up in both treatment-naïve (n = 179) and treatment-experienced (n = 290) groups. Body mass index (BMI) categories changed over time for TAF/F/EVG/c and ABC/3TC/DTG, with significant increases in the rates of overweight and obesity in treatment-naïve patients, whereas there was no change for TDF/F/EVG/c. TAF/F/EVG/c significantly increased total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and triglyceride (TG) compared to other regimens over 24 months. In the treatment-naïve group, a baseline CD4+ T cell count <100 cells/mm3, human immunodeficiency virus (HIV) viral load (VL) ≥100,000 copies/mL, no physical exercise, and TAF/F/EVG/c (vs. TDF/F/EVF/c) were risk factors for ≥10% weight gain. In the treatment-experienced group, age <45 years, BMI <25 kg/m2, and no physical exercise were risk factors for ≥5% weight gain. Conclusion INSTI-based STR continued to increase body weight at the 24-month follow up in treated and untreated Korean PLWH. Exercise, together with demographic-, HIV-, and anti-retroviral therapy-related factors, influenced weight gain. Therefore, when prescribing an INSTI-based STR, weight gain and metabolic changes should be closely monitored in PLWH with these risk factors.
목차
등록된 정보가 없습니다.
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in Asian Subjects with Human Immunodeficiency Virus 1 Infection: A Sub- Analysis of Phase 3 Clinical Trials
Infection and Chemotherapy
2016 .01
-
Effects of Korean Red Ginseng combination therapy on HIV-infected patients treated with integrase strand transfer inhibitors
Journal of Ginseng Research
2024 .11
-
Recovery of Tenofovir-induced Nephrotoxicity following Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Human Immunodeficiency Virus-Positive Patients
Infection and Chemotherapy
2020 .01
-
Electroanatomical Mapping of the Urinary Bladder
International Neurourology Journal
2016 .01
-
Integrase Strand Transfer Inhibitor Resistance Mutations in Antiretroviral Treatment-naïve Patients in Korea: a Prospective, Observational Study
Journal of Korean Medical Science
2018 .01
-
사람면역결핍바이러스 감염인 및 후천면역결핍증후군 환자 지원을 위한 보건의료정책
대한의사협회지
2024 .03
-
Similar Durability of Two Single Tablet Regimens, Dolutegravir/Abacavir/Lamivudine and Elvitegravir/Cobicistat/Tenofovir/Emtricitabine: Single Center Experience
Journal of Korean Medical Science
2020 .01
-
Effectiveness and Tolerability of Dual Therapy with Dolutegravir Plus Darunavir/cobicistat in Treatment-Experienced Patients with HIV: A 144-Week Follow-Up
Infection and Chemotherapy
2024 .06
-
Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide in patients with chronic hepatitis B: More questions than an answer
Clinical and Molecular Hepatology
2024 .04
-
Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide
Clinical and Molecular Hepatology
2024 .01
-
Effectiveness, Safety, and Tolerability of a Switch to Dual Therapy with Dolutegravir Plus Cobicistat-Boosted Darunavir in Treatment-Experienced Patients with Human Immunodeficiency Virus
Infection and Chemotherapy
2018 .01
-
The Story and Implications of the Korean Health Care Facility Counseling Project on People Living with HIV
Infection and Chemotherapy
2023 .06
-
Prevalence of hypertension among antiretroviral therapy naïve patients in Lagos, Nigeria
Clinical Hypertension
2023 .01
-
Korean Version of the Thought-Action Fusion Scale: The Evidence for Its Psychometric Properties
PSYCHIATRY INVESTIGATION
2021 .01
-
The Incidence and Clinical Characteristics of Acute Serum Creatinine Elevation more than 1.5 mg/dL among the Patients Treated with Tenofovir/ Emtricitabine-containing HAART Regimens
Infection and Chemotherapy
2015 .01
-
Effect of Korean Red Ginseng intake on the survival duration of human immunodeficiency virus type 1 patients
Journal of Ginseng Research
2017 .04
-
Tenofovir-induced renal tubular dysfunction among human immunodeficiency virus patients on antiretroviral therapy in Nigeria: Prospects for early detection of presymptomatic nephrotoxicity
Kidney Research and Clinical Practice
2018 .01
-
HIV 감염인을 위한 완화의료와 호스피스
한국호스피스·완화의료학회지
2017 .01
-
Renal Disease in Persons Infected with Human Immunodeficiency Virus in Korea
Infection and Chemotherapy
2017 .01
-
Weight Gain, Comorbidities, and Its Associated Factors Among Korean Adults
Journal of Korean Medical Science
2023 .03
이 논문의 저자 정보
최근 본 자료
댓글(0)
0